Composition for treating chronic prostatitis as well as preparation method and application thereof

Abstract

The invention discloses a composition for treating chronic prostatitis and a preparation method and application thereof. The composition is prepared from, by mass, 8-15 parts of cortex cinnamomi, 5-7 parts of radix et rhizoma rhei, 1-2 parts of borneol, 5-8 parts of fructus foeniculi, 2-5 parts of flos caryophylli and 5-7 parts of herba verbenae. The Shenque acupoint external application is adopted, the medicine can permeate into viscera meridians and collaterals through the Shenque acupoint to achieve the treatment effect, the medicine applied to the umbilical region is not metabolized by the liver, stimulation of the medicine to the digestive tract and damage of the first pass effect of the liver to effective components of the medicine are avoided, and the treatment effect can be better achieved. Clinical tests show that the total effective rate of the medicine reaches 86.5%, and the medicine can effectively treat chronic prostatitis.

Description

Technical Field

[0001] The invention relates to the technical field of traditional Chinese medicines, and in particular to a composition for treating chronic prostatitis, a preparation method and an application thereof. Background Art

[0002] Prostatitis is an inflammatory reaction caused by infection of the prostate by pathogens such as microorganisms or stimulation by certain non-infectious factors, and the resulting clinical manifestations such as discomfort or pain in the prostate area and abnormal urination in patients. It is a common and very confusing disease. The concept of prostatitis mainly emphasizes the three basic elements of lower urinary tract symptoms, inflammation and prostate involvement, and the degree of manifestation of each element can vary greatly. Prostatitis includes acute prostatitis and chronic prostatitis. If the patient has symptoms related to prostatitis syndrome and systemic infection and poisoning symptoms, it can be determined as acute prostatitis. If the patient has symptoms related to prostatitis syndrome and does not have systemic infection and poisoning symptoms, and self-adjustment after an appropriate period of time is ineffective, it is diagnosed as chronic prostatitis. Chronic prostatitis is not an independent disease, but only a comprehensive disease or syndrome with similar clinical manifestations but their own unique forms. This syndrome has unique etiology, clinical characteristics and outcomes.

[0003] The etiology of chronic prostatitis is complex, and Chinese medicine often treats it based on "turbid semen". "Treatise on the Causes and Symptoms of Various Diseases" says: "All stranguria is caused by kidney deficiency and damp heat in the bladder... Kidney deficiency leads to frequent urination, and bladder heat makes the urine difficult to pass. Frequent and difficult urination leads to stranguria." Another example is "The Complete Book of Peeling Drama" says: "There are red and white turbid stool syndromes, and there is a distinction between semen and urine. All red ones are mostly caused by fire, and white ones can be caused by both cold and heat. Those that are turbid due to semen move in the heart and kidney, and those that are turbid due to urine move in the bladder, liver and kidney." It also says: "Turbid syndrome... If there is heat, the heart and kidney should be distinguished to clear it, and if there is no heat, the spleen and kidney should be sought to consolidate and lift it. There is no mistake in treating turbidity. "Standards for Diagnosis and Efficacy of Chinese Medicine Diseases and Symptoms" named prostatitis as turbid semen; those that are turbid move in the heart and kidney, and those that are turbid due to urine move in the bladder, liver and kidney." It also says: "The turbid syndrome...if there is heat, we should distinguish the heart and kidney, and the bladder is damp-heat...If the kidney is deficient, the urination will be frequent, and if the bladder is hot, the urine will be sticky. If it is frequent and sticky, it will be drizzling." Another example is in "Jingyue Complete Works": "The turbid stool syndrome is divided into red and white, and there is a distinction between seminal urine. All red ones are mostly caused by fire, and white ones are both cold and hot, caused by seminal deficiency and hyperactivity of fire, and stasis in the seminal chamber. In the early stage of this disease, damp-heat is often seen, in the middle stage, it is mostly damp-heat stasis, and in the late stage, it is often accompanied by spleen and kidney deficiency. Dampness, heat, stasis, stagnation and deficiency run through the different stages of chronic prostatitis. Cui Xuejiao believes that chronic prostatitis is a syndrome of deficiency in the root and excess in the superficial. Deficiency is liver and kidney yin deficiency, and excess is caused by stasis, heat, and dampness. The disease lasts for a long time, and deficiency and excess are mixed. Yin and Yang are Difficult to treat. Ding Guangdi believes that this disease is the "leucorrhea" in traditional Chinese medicine. The root of the disease lies between the heart and kidney and the liver and kidney. It is closely related to the heart, liver and kidney. The overall pathological changes are yin deficiency and yang excess, with deficiency at the root and excess at the superficial level. Through clinical analysis, Sun Zixue pointed out that liver and kidney deficiency is the basic pathogenesis of the disease, the invasion of damp-heat toxins is the key to its occurrence, qi deficiency and blood stasis are the inevitable results of the development of the disease, and the overall pathogenesis is a mixture of deficiency and excess. Dai Xihu believes that chronic prostatitis has liver depression, dampness obstruction, and blood stasis as the main contradictions, and the treatment should focus on soothing the liver, removing dampness, and removing blood stasis. Li Yueqing believes that for most patients with early and middle-stage chronic prostatitis, the most common pathogenesis is damp-heat and blood stasis. Jiang Hai Shen et al. pointed out that chronic prostatitis is closely related to the extraordinary meridians, and believed that the heat of this disease is caused by the fire of the phase, which disturbs the sperm chamber and can move to the bladder. This is a disease of the sperm channel and the water channel, rather than a urinary tract infection that is purely a water channel disease. From the perspective of anatomical location, the prostate is consistent with the "essence gate" and "blood chamber" in traditional Chinese medicine, with a deeper level, and it belongs to the extraordinary meridians (Ren, Chong, and Du meridians), which are difficult for general medicines to reach. In short, looking at the understanding of various schools, the etiology and pathogenesis of chronic prostatitis are nothing more than deficiency and excess. Deficiency is kidney deficiency and qi deficiency, and excess is qi stagnation, damp heat, and blood stasis. The affected organs are mainly liver, kidney, heart, and spleen. It is a syndrome of deficiency in the root and excess in the superficial, and most of the clinical cases are deficiency and excess.

[0004] There are many drugs and methods for treating chronic prostatitis at home and abroad, most of which are oral antibiotics. Taking antibiotics to treat chronic prostatitis does not kill bacteria and clear the source, and it only treats the symptoms but not the root cause. It is not only ineffective, but also may lead to increased drug resistance of bacteria and worsening of the condition. Summary of the invention

[0005] The object of the present invention is to provide a composition for treating chronic prostatitis, a preparation method and an application thereof, so as to at least solve the above-mentioned technical problems.

[0006] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0007] On the one hand, the present invention discloses a composition for treating chronic prostatitis, comprising the following raw materials in parts by weight: 8-15 parts of cinnamon, 5-7 parts of rhubarb, 1-2 parts of borneol, 5-8 parts of fennel, 2-5 parts of cloves, and 5-7 parts of verbena.

[0008] Furthermore, the invention comprises the following raw materials in parts by weight: 8 to 12 parts of cinnamon, 5 to 6 parts of rhubarb, 1.2 to 2 parts of borneol, 5 to 6 parts of fennel, 3 to 5 parts of cloves, and 5 to 6 parts of verbena.

[0009] Furthermore, the invention comprises the following raw materials in parts by mass: 10 parts of cinnamon, 6 parts of rhubarb, 1.5 parts of borneol, 6 parts of fennel, 3 parts of cloves and 6 parts of verbena.

[0010] Furthermore, the composition is added with conventional pharmaceutical excipients to prepare a clinically acceptable dosage form.

[0011] Furthermore, the dosage form is a dressing or an ointment.

[0012] In another aspect, the present invention discloses a method for preparing a composition for treating chronic prostatitis, comprising the following steps:

[0013] S1. Mix and grind cinnamon, rhubarb, borneol, fennel, cloves and verbena in different weight parts into powder;

[0014] S2. Use rice wine to adjust the powder into a paste-like compress, or use glycerin and add laurocapram, mixed fatty acid glycerides and beeswax to adjust it into a paste-like ointment.

[0015] Furthermore, the amount of glycerol added is 12 to 15 parts.

[0016] Furthermore, the amount of laurocapram added is 2% of the total mass of the raw material.

[0017] In S2, the mixed fatty acid glyceride and the beeswax are added in appropriate amounts, and other ingredients may also be added in appropriate amounts.

[0018] In a third aspect, the present invention also discloses the use of the above composition in the preparation of a drug for preventing and / or treating chronic prostatitis.

[0019] Furthermore, the medicine is an external medicine, and its medicinal site is the Shenque point.

[0020] The method for using the medicine for treating chronic prostatitis of the present invention comprises applying 5g of the medicine on a blank medicine patch each time, applying the medicine patch on the Shenque acupoint at room temperature, retaining the medicine patch for 12 hours, and replacing the medicine patch with a new one after an interval of 12 hours.

[0021] Furthermore, one application is considered as one treatment, 8 applications are considered as one course of treatment, and 2 courses of treatment are performed continuously with a 2-day rest period between courses.

[0022] The cinnamon bark in the present invention is the dried bark of the cinnamon bark of the Lauraceae plant Cinnamomum cassia Presl. It is pungent, sweet and very hot. It enters the kidney, spleen, heart and liver meridians. It has the effects of replenishing fire and yang, guiding fire back to the origin, dispelling cold and relieving pain, and warming and unblocking the meridians.

[0023] The rhubarb in the present invention is the dried root and rhizome of Rheum palmatum L., Rheumtanguticum Maxim.ex Balf. or Rheum officinale Baill. of the Polygonaceae family. It is bitter in taste, cold in nature, and enters the spleen, stomach, large intestine, liver, and pericardium meridians. It has the effects of purging and attacking accumulation, clearing away heat and purging fire, cooling blood and detoxifying, removing blood stasis and promoting menstruation, and removing dampness and relieving jaundice.

[0024] The borneol in the present invention is made by extracting and processing fresh branches and leaves of Cinnamomum camphora (L.) Presl, a plant of Lauraceae. It is pungent and bitter in taste and cool in nature. It enters the heart, spleen and lung meridians and has the effects of invigorating the mind, clearing away heat and relieving pain.

[0025] The fennel in the present invention is the dried mature fruit of the Umbelliferae plant Foeniculum vulgare Mill. It is pungent in taste and warm in nature. It enters the liver, kidney, spleen and stomach meridians. It has the effects of dispelling cold and relieving pain, regulating qi and harmonizing the stomach.

[0026] The clove in the present invention is the dried flower bud of Eugenia caryophyllata Thunb. of the Myrtaceae family. It is pungent in taste and warm in nature. It enters the spleen, stomach, lung and kidney meridians. It has the effects of warming the middle and relieving adverse reactions, and tonifying the kidney and assisting yang.

[0027] The verbena in the present invention is the dried aerial part of the verbena plant Verbena officinalis L. of the Verbenaceae family. It is bitter in taste and cool in nature. It enters the liver and spleen meridians. It has the effects of promoting blood circulation, dispersing blood stasis, detoxifying, promoting diuresis, relieving jaundice and stopping malaria.

[0028] The present invention uses cinnamon and clove as main drugs, because of their warming properties, they have the effect of promoting qi and relieving pain, so the treatment effect of pain caused by cold is good;

[0029] The invention uses fennel as the ministerial drug, which warms the interior, dispels cold, and regulates qi, has significant therapeutic effects on cold hernia abdominal pain, testicular swelling and pain, etc., and strengthens the efficacy of the monarch drug;

[0030] The invention uses rhubarb as an adjuvant, which has the effects of purging heat and clearing the intestines, cooling blood and detoxifying, and removing blood stasis and promoting menstruation.

[0031] The invention uses borneol as a guiding drug, which has the effects of clearing away heat, purging fire, cooling blood and detoxifying. The menthol in the special volatile oil component can stimulate the expansion of capillaries, promote blood circulation and harmonize various drugs.

[0032] Compared with the prior art, the present invention has the following beneficial effects:

[0033] The invention has a scientific formula and adopts the external application of Shenque acupoint. The center of the navel is Shenque acupoint, which belongs to the sea of ​​yin meridians - Renmai. Renmai and Dumai are exterior and interior to each other, and have a very close relationship with the viscera and meridians. The drug can penetrate into the viscera and meridians through the Shenque acupoint to play a therapeutic role. Shenque acupoint plays an important role in the occurrence, development and treatment of diseases. Umbilical medication does not undergo liver metabolism, avoids drug stimulation to the digestive tract, and the destruction of the active ingredients of the drug by the first-pass effect of the liver, and can better exert the therapeutic effect. DETAILED DESCRIPTION

[0034] In order to make the purpose, technical scheme and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making creative work are within the scope of protection of the present invention.

[0035] Example 1

[0036] As a preferred embodiment of the present invention, a medicine for treating chronic prostatitis disclosed in this embodiment includes the following raw materials in parts by mass: 8 parts of cinnamon, 7 parts of rhubarb, 2 parts of borneol, 5 parts of fennel, 5 parts of cloves, and 6 parts of verbena.

[0037] The above-mentioned raw materials are proportioned and ground into 80-mesh powder; 13 parts of glycerin are used and supplemented with laurocapram, mixed fatty acid glycerides and beeswax to make a paste-like ointment, the amount of laurocapram added is 2% of the total mass of the raw materials, and the amount of mixed fatty acid glycerides and beeswax added is 1 part each.

[0038] The method of using the drug in this embodiment is as follows: 5 g of the drug is applied to a blank patch each time, and the patch is applied to the Shenque acupoint at room temperature for 12 hours, and a new patch is replaced after an interval of 12 hours. One application is one treatment, 8 times is one course of treatment, and two courses of treatment are continued, with a 2-day rest between courses.

[0039] Example 2

[0040] As a preferred embodiment of the present invention, a medicine for treating chronic prostatitis disclosed in this embodiment includes the following raw materials in parts by mass: 15 parts of cinnamon, 5 parts of rhubarb, 1 part of borneol, 8 parts of fennel, 2 parts of cloves, and 7 parts of verbena.

[0041] The above-mentioned raw materials are proportioned and ground into 80-mesh powder; 14 parts of glycerin are used and supplemented with laurocapram, mixed fatty acid glycerides and beeswax to make a paste-like ointment, the amount of laurocapram added is 2% of the total mass of the raw materials, and the amount of mixed fatty acid glycerides and beeswax added is 1 part each.

[0042] The method of using the drug in this embodiment is as follows: 5 g of the drug is applied to a blank patch each time, and the patch is applied to the Shenque acupoint at room temperature for 12 hours, and a new patch is replaced after an interval of 12 hours. One application is one treatment, 8 times is one course of treatment, and two courses of treatment are continued, with a 2-day rest between courses.

[0043] Example 3

[0044] As a preferred embodiment of the present invention, a drug for treating chronic prostatitis disclosed in this embodiment comprises the following raw materials in parts by weight: 10 parts of cinnamon, 6 parts of rhubarb, 1.5 parts of borneol, 6 parts of fennel, 3 parts of cloves, and 6 parts of verbena;

[0045] The above-mentioned raw materials are proportioned and ground into 80-mesh powder; 15 parts of glycerin are used and supplemented with laurocapram, mixed fatty acid glycerides and beeswax to make a paste-like ointment, the amount of laurocapram added is 2% of the total mass of the raw materials, and the amount of mixed fatty acid glycerides and beeswax added is 1 part each.

[0046] The method of using the drug in this embodiment is as follows: 5 g of the drug is applied to a blank patch each time, and the patch is applied to the Shenque acupoint at room temperature for 12 hours, and a new patch is replaced after an interval of 12 hours. One application is one treatment, 8 times is one course of treatment, and two courses of treatment are continued, with a 2-day rest between courses.

[0047] Example 4

[0048] As a preferred embodiment of the present invention, a drug for treating chronic prostatitis disclosed in this embodiment comprises the following raw materials in parts by weight: 10 parts of cinnamon, 6 parts of rhubarb, 1.5 parts of borneol, 6 parts of fennel, 3 parts of cloves, and 6 parts of verbena;

[0049] The above raw materials are proportioned and ground into 80 mesh powder; the powder is adjusted with rice wine to a paste-like poultice.

[0050] The method of using the drug in this embodiment is as follows: 5 g of the drug is applied to a blank patch each time, and the patch is applied to the Shenque acupoint at room temperature for 12 hours, and a new patch is replaced after an interval of 12 hours. One application is one treatment, 8 times is one course of treatment, and two courses of treatment are continued, with a 2-day rest between courses.

[0051] Test Example 1

[0052] This test example discloses the clinical trial research data of the composition of the present invention. The details are as follows:

[0053] 1. General Information

[0054] Fifty patients with chronic prostatitis were selected, aged between 20 and 60 years old, with an average age of 36 years. The longest history of the disease was 21 years, the shortest was half a year, and the average was 5 years.

[0055] 2. Diagnostic criteria and efficacy assessment criteria

[0056] Symptoms: Patients experience lower urinary tract symptoms such as frequent urination, urgency, dysuria, residual urine, and discomfort or pain in the perineum, inguinal area, retropubic area, and testicular scrotum, with or without neurological symptoms such as insomnia and anxiety.

[0057] Signs: Tenderness or distending pain may occur when the prostate is palpated, and nodules or swollen glands may be felt locally.

[0058] Laboratory examination: Prostatic fluid or urine culture can reveal bacterial infection or elevated white blood cell counts. At the same time, it is necessary to rule out similar symptoms caused by other diseases, such as prostatic hyperplasia and prostate cancer.

[0059] cure:

[0060] (1) Subjective symptoms disappear.

[0061] (2) Prostate tenderness disappears and the texture becomes softer or improves during palpation.

[0062] (3) The segmented urine test is normal.

[0063] (4) The white blood cell count in microscopic examination of prostatic fluid is less than 10 / HP, bacterial culture is negative, and the result is normal for more than 2 consecutive examinations.

[0064] Significant effect:

[0065] (1) Subjective symptoms disappear.

[0066] (2) Palpation of the prostate gland is normal or improved.

[0067] (3) The white blood cell count in prostatic fluid microscopy is >10 / HP, or bacterial culture is still positive.

[0068] efficient:

[0069] (1) Some symptoms improve or disappear.

[0070] (2) The white blood cell count in prostatic fluid microscopy was better than before treatment, but bacterial culture was still positive.

[0071] invalid:

[0072] (1) There was no improvement in symptoms and microscopic examination of prostatic fluid.

[0073] 3. Treatment methods

[0074] The medicine prepared by the formula of Example 3. The method of use is as follows: 5 g of the medicine is applied to a blank patch each time, and the patch is applied to the Shenque point at room temperature, and kept for 12 hours, and a new patch is replaced after an interval of 12 hours. One application is one treatment, 8 times is one course of treatment, and two courses of treatment are continued, with a 2-day rest between courses.

[0075] 4. Treatment results

[0076] Through clinical observation of 50 patients with chronic prostatitis, 15 were cured by the drug of the present invention, 13 were markedly effective, 17 were effective, 5 patients discontinued treatment, 6 patients developed a small rash on the navel after taking the drug and recovered on their own after rest, and the total effective rate was 86.5%.

[0077] The present invention adopts external application of Shenque acupoint, the center of the navel is Shenque acupoint, which belongs to the sea of ​​yin meridians - Renmai, which is the exterior and interior of Du meridian and has a very close relationship with viscera and meridians. Drugs can penetrate into viscera and meridians through Shenque acupoint to play a therapeutic role. Shenque acupoint plays an important role in the occurrence, development and treatment of diseases. Umbilical medication does not undergo liver metabolism, avoids drug stimulation to the digestive tract, and the destruction of the active ingredients of the drug by the first-pass effect of the liver, and can better exert the therapeutic effect.

[0078] Finally, it should be noted that the above embodiments are only preferred embodiments of the present invention to illustrate the technical solutions of the present invention, rather than limiting them, and certainly not limiting the patent scope of the present invention. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions recorded in the aforementioned embodiments, or replace some or all of the technical features therein by equivalents. These modifications or replacements do not make the essence of the corresponding technical solutions deviate from the scope of the technical solutions of the embodiments of the present invention. In other words, any changes or modifications made to the main design concept and spirit of the present invention that have no substantive significance, and the technical problems they solve are still consistent with the present invention, should be included in the protection scope of the present invention. In addition, the direct or indirect application of the technical solutions of the present invention in other related technical fields is also included in the patent protection scope of the present invention.

Claims

1. A composition for treating chronic prostatitis, characterized in that: The invention comprises the following raw materials in parts by weight: 8-15 parts of cinnamon, 5-7 parts of rhubarb, 1-2 parts of borneol, 5-8 parts of fennel, 2-5 parts of cloves and 5-7 parts of verbena.

2. A composition for treating chronic prostatitis according to claim 1, characterized in that: It includes the following raw materials in parts by mass: 8-12 parts of cinnamon, 5-6 parts of rhubarb, 1.2-2 parts of borneol, 5-6 parts of fennel, 3-5 parts of cloves, and 5-6 parts of verbena.

3. A composition for treating chronic prostatitis according to claim 1, characterized in that: The invention comprises the following raw materials in parts by mass: 10 parts of cinnamon, 6 parts of rhubarb, 1.5 parts of borneol, 6 parts of fennel, 3 parts of cloves and 6 parts of verbena.

4. A composition for treating chronic prostatitis according to claim 1, characterized in that: The composition is added with conventional pharmaceutical excipients to prepare a clinically acceptable dosage form.

5. A composition for treating chronic prostatitis according to claim 4, characterized in that: The dosage form is a dressing or an ointment.

6. A method for preparing a composition for treating chronic prostatitis according to any one of claims 1 to 5, characterized in that: The following steps are involved: S1. Mix and grind cinnamon, rhubarb, borneol, fennel, cloves and verbena in different weight parts into powder; S2. Use rice wine to adjust the powder into a paste-like compress, or use glycerin and add laurocapram, mixed fatty acid glycerides and beeswax to adjust it into a paste-like ointment.

7. The method for preparing a drug for treating chronic prostatitis according to claim 6, characterized in that: The added amount of the glycerol is 12 to 15 parts.

8. The method for preparing a drug for treating chronic prostatitis according to claim 6, characterized in that: The added amount of laurocapram is 2% of the total mass of the raw material medicine.

9. Use of the composition according to any one of claims 1 to 5 in the preparation of a medicament for preventing and / or treating chronic prostatitis.

10. The use according to claim 9, characterized in that: The medicine is for external use, and its medicinal site is the Shenque point.